CN110115387A - 一种乳铁蛋白片保健食品及其生产方法 - Google Patents
一种乳铁蛋白片保健食品及其生产方法 Download PDFInfo
- Publication number
- CN110115387A CN110115387A CN201810148882.4A CN201810148882A CN110115387A CN 110115387 A CN110115387 A CN 110115387A CN 201810148882 A CN201810148882 A CN 201810148882A CN 110115387 A CN110115387 A CN 110115387A
- Authority
- CN
- China
- Prior art keywords
- lactoferrin
- grams
- piece
- health food
- mixed powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000010445 Lactoferrin Human genes 0.000 title claims abstract description 39
- 108010063045 Lactoferrin Proteins 0.000 title claims abstract description 39
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims abstract description 39
- 229940078795 lactoferrin Drugs 0.000 title claims abstract description 39
- 235000021242 lactoferrin Nutrition 0.000 title claims abstract description 39
- 235000013402 health food Nutrition 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 210000003022 colostrum Anatomy 0.000 claims abstract description 16
- 235000021277 colostrum Nutrition 0.000 claims abstract description 16
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000004225 ferrous lactate Substances 0.000 claims abstract description 12
- 235000013925 ferrous lactate Nutrition 0.000 claims abstract description 12
- 229940037907 ferrous lactate Drugs 0.000 claims abstract description 12
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 10
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 7
- 241000283690 Bos taurus Species 0.000 claims abstract description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 239000011812 mixed powder Substances 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 108010011485 Aspartame Proteins 0.000 claims description 9
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 9
- 229960003438 aspartame Drugs 0.000 claims description 9
- 235000010357 aspartame Nutrition 0.000 claims description 9
- 239000000605 aspartame Substances 0.000 claims description 9
- 229940072440 bovine lactoferrin Drugs 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 235000015165 citric acid Nutrition 0.000 claims description 7
- 238000005469 granulation Methods 0.000 claims description 6
- 230000003179 granulation Effects 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 235000020985 whole grains Nutrition 0.000 claims description 6
- 229960004106 citric acid Drugs 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 239000000080 wetting agent Substances 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 4
- 238000007689 inspection Methods 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 3
- 238000012797 qualification Methods 0.000 claims description 3
- 239000011122 softwood Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- -1 D-mannital Chemical compound 0.000 claims description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims 1
- 235000013339 cereals Nutrition 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 230000036039 immunity Effects 0.000 abstract description 8
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 238000005457 optimization Methods 0.000 abstract description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 26
- 238000000034 method Methods 0.000 description 18
- 229910052742 iron Inorganic materials 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 206010022971 Iron Deficiencies Diseases 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 102100033468 Lysozyme C Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- BUCXEFZXWKUCCY-UHFFFAOYSA-N 4-methyl-3-(2-phenylethyl)-1,2,4-oxadiazol-5-one Chemical compound O1C(=O)N(C)C(CCC=2C=CC=CC=2)=N1 BUCXEFZXWKUCCY-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000036365 Normal labour Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000002070 Transferrins Human genes 0.000 description 1
- 108010015865 Transferrins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002229 photoelectron microspectroscopy Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种乳铁蛋白片保健食品及其生产方法,每1000克由下述重量的原料制备而成:乳铁蛋白100克、牛初乳粉400克、乳酸亚铁12.9克、低聚半乳糖227.5克以及赋形剂。本发明通过优化各组分用量,最大程度保证了主要组分在提高机体免疫能力方面的协同作用,确保了本发明增强免疫力的功效。本发明乳铁蛋白片携带和服用方便。
Description
技术领域
本发明涉及保健食品技术领域,具体涉及一种可增强免疫力的乳铁蛋白片,本发明还涉及该乳铁蛋白片的生产方法。
背景技术
乳铁蛋白是一种非血红素铁结合性糖蛋白,属于转铁蛋白家族。对于其功能研究最早是关于其结合铁的特性。在近半个世纪的研究中,发现乳铁蛋白有着更广泛的生物功能。包括广谱抗菌、抗病毒,调节体内铁平衡,促进骨髓细胞生成,促进细胞生长,增强机体免疫抗病能力,抑制肿瘤细胞,能与多种抗生素及抗真菌制剂协同作用,更有效治疗疾病等。研究表明,乳铁蛋白可以通过多种途径影响机体的免疫功能。
牛初乳是奶牛正常分娩后一周内分泌的乳汁,它含有丰富的营养物质和多种免疫活性因子、生长因子,在动物和人体保健中的作用受到日益广泛的重视,2000年被美国食品科技协会(IEF)列为21世纪最佳发展前景的非草药类天然健康食品,有“免疫之王”、“乳黄金”之称,现已成为新一代功能性食品资源库。研究表明,牛初乳中的主要免疫调节因子有免疫球蛋白、乳铁蛋白、细胞因子。此外,牛初乳中的溶菌酶、过氧化物酶(LP)、富含脯氨酸的多肽(PRP)及其降解产物、酪蛋白和其他乳清蛋白降解产物等也具有免疫调节功能。
铁是动物体内必须的微量元素铁和含铁蛋白有很复杂的生物学功能,缺铁可引起多种组织改变和功能失调,骨髓有核细胞DNA和RNA含量减少。缺铁时与杀菌有关的含铁酶或依赖酶活性明显降低,可导致淋巴细胞DNA的合成受阻,抗体产生被抑制,干扰溶菌酶的活性,白细胞杀菌功能减弱,淋巴细胞对特别抗原的反应效能降低,机体对感染的应激能力下降,因此易受感染。感染后的红细胞破坏加速,死亡率升高。研究表明,铁与机体免疫有着重要的联系,缺铁会对机体免疫造成很多不良影响。
为了进一步提高乳铁蛋白粉的保健效果和发挥各成分的协同作用,特别是增强机体的免疫能力,需要对各成分的用量、产品的质量控制以及生产方法等进行优化。
发明内容
本发明的目的在于克服现有技术的不足,提供一种配方合理、服用方便、可提高免疫力的乳铁蛋白片保健食品。
为实现以上本发明的目的,本发明采用如下的技术方案:
一种乳铁蛋白片保健食品,所述乳铁蛋白片由乳铁蛋白、牛初乳粉、乳酸亚铁以及赋形剂制备而成。
进一步地,上述乳铁蛋白片每1000克由下述重量的原料制备而成:
乳铁蛋白100克、、牛初乳粉400克、乳酸亚铁12.9克、低聚半乳糖227.5克、余下为赋形剂。
上述赋形剂优选为:D-甘露糖醇45克、柠檬酸9.6克、阿斯巴甜3克、硬脂酸镁2克。
本发明一种乳铁蛋白片保健食品的生产方法,包括如下步骤:
(1)过筛
将乳铁蛋白、牛初乳粉、乳酸亚铁、低聚半乳糖、柠檬酸、阿斯巴甜、D-甘露糖醇、硬脂酸镁分别过80目筛,称量备用;
(2)混合
将柠檬酸、阿斯巴甜和乳酸亚铁混合均匀,得混合粉1,将混合粉1和D-甘露糖醇按混合均匀,得混合粉2;将混合粉2、乳铁蛋白、牛初乳粉、低聚半乳糖置混合机中,混合20min,得总混合粉;
(3)制粒、干燥、整粒
用纯化水做润湿剂,制软材,过18目筛制颗粒;湿颗粒用热风循环烘箱干燥;所得干颗粒用16目筛整粒;
(4)总混、压片
将上述备用的硬脂酸镁加入所得颗粒中,置混合机混合5min,得总混颗粒;将上述所得总混颗粒压片,调节片重为0.8g/片;
(5)包装
用口服固体药用高密度聚乙烯瓶将上述所得合格片子进行包装;口服固体药用高密度聚乙烯瓶应符合国家药品包装容器(材料)标准YBB00122002的要求;
(6)成品检验、入库
按照本产品企业标准规定抽取每批产品进行检验,将合格的产品进行入库。
进一步地,步骤(3)所述的制粒、干燥、整粒中:
润湿剂的用量优选为总混合粉的30%;
干燥温度优选为50~55℃;
干燥时间优选为30~40min。
上述生产过程中过筛、混合、制粒、干燥、整粒、总混、压片、内包装等工序均在符合GB17405-1998要求的三十万级生产洁净区条件下操作,其他工序在一般生产区,生产环境及管理应符合保健食品生产管理规范的要求。
与现有技术相比,本发明具有的有益效果如下:
本发明采用乳铁蛋白、牛初乳粉、乳酸亚铁作为原料进行配方,通过优化各组分用量,最大程度保证了主要组分在提高机体免疫能力方面的协同作用,确保了本发明增强免疫力的功效。本发明所使用的主要原料及用量均符合相关规定,所采用的原料均是国家允许所用的保健食品原料。
本发明乳铁蛋白片携带和服用方便,提高了使用者的依从性,确保了保健功效。本发明生产过程中以蛋白质、免疫球蛋白IgG和铁作为该产品的标志性成分进行质量控制,每100g产品含蛋白质26.6g、免疫球蛋白IgG 8.3g以及铁298mg,较好地解决了现有保健产品质量不稳定以及保健效果不确切的技术问题。
具体实施方式
为便于理解本发明,本发明列举实施例如下。如无具体说明,本发明的各种原料均可以通过市售得到;或根据本领域的常规方法制备得到。除非另有定义或说明,本文中所使用的所有专业与科学用语与本领域技术熟练入员所熟悉的意义相同。此外任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。除非另外说明,本文中所使用的所有专业与科学用语与本领域技术熟练人员所熟悉的意义相同。
每1000克乳铁蛋白片的配方如下:
乳铁蛋白100克、、牛初乳粉400克、乳酸亚铁12.9克、低聚半乳糖227.5克、D-甘露糖醇45克、柠檬酸9.6克、阿斯巴甜3克、硬脂酸镁2克。
生产方法具体如下:
(1)过筛
将乳铁蛋白、牛初乳粉、乳酸亚铁、低聚半乳糖、柠檬酸、阿斯巴甜、D-甘露糖醇、硬脂酸镁分别过80目筛,称量备用;
(2)混合
将柠檬酸、阿斯巴甜和乳酸亚铁混合均匀,得混合粉1,将混合粉1和D-甘露糖醇按混合均匀,得混合粉2;将混合粉2、乳铁蛋白、牛初乳粉、低聚半乳糖置混合机中,混合20min,得总混合粉;
(3)制粒、干燥、整粒
用纯化水做润湿剂,用量为总混合粉的30%,制软材,过18目筛制颗粒;湿颗粒用热风循环烘箱干燥;干燥温度为55℃,干燥时间为30;所得干颗粒用16目筛整粒;
(4)总混、压片
将上述备用的硬脂酸镁加入所得颗粒中,置混合机混合5min,得总混颗粒;将上述所得总混颗粒压片,调节片重为0.8g/片;
(5)包装
用口服固体药用高密度聚乙烯瓶将上述所得合格片子进行包装;
(6)成品检验、入库
按照本产品企业标准规定抽取每批产品进行检验,将合格的产品进行入库。
一、以蛋白质、免疫球蛋白IgG和铁作为该产品的标志性成分进行质量控制,将本实施例制得的乳铁蛋白片按下述方法进行测定:
1、蛋白质按照按《GB 5009.5食品安全国家标准食品中蛋白质的测定》中的方法进行;免疫球蛋白IgG按《保健食品检验与技术评价规范》(2003版)中的方法进行;铁的检测按《GB/T 5009.90-2003食品中铁、镁、锰的测定》中的方法进行。
2、测定结果显示:每100g乳铁蛋白粉产品含蛋白质26.6g、免疫球蛋白IgG 8.3g以及铁298mg。
二、将本实施例制得的乳铁蛋白片,进行如下增强免疫力功能测试试验:
1、依据:《保健食品检验与评价技术规范》2003年版。
2、动物分组:釆用SPF级雄性Balb/c小鼠,分为空白对照组、低剂量组(250mg/kg.bw)、中剂量组(500mg/kg.bw)和高剂量组(750mg/kg.bw);每日一次灌胃,连续灌胃30天。
3、检测指标包括:脏器/体重比值、ConA诱导的小鼠淋巴细胞转化实验(MTT法)、迟发型变态反应(DTH,足趾增厚法)、血清溶血素测定(血凝法)、抗体生成细胞检测(Jerne改良玻片法)、小鼠腹腔巨噬细胞鸡红细胞实验(半体内法)、小鼠碳廓清实验、NK细胞活性测定(乳酸脱氢酶测定法)。
4、数据统计:用PEMS for Windows 3.1统计软件包进行方差分析,方差不齐用秩和检验统计。
5、结果
(1)、在ConA诱导的小鼠淋巴细胞转化实验(MTT法)中,本实施例的乳铁蛋白片高剂量组(750mg/kg.bw)OD值差值显著高于空白对照组(P<0.05);
(2)、在迟发型变态反应(DTH,足趾增厚法)中,本实施例的乳铁蛋白片高剂量组(750mg/kg.bw)足趾老增厚程度显著高于空白对照组(P<0.05);
(3)、在血清溶血素测定(血凝法)中,本实施例的乳铁蛋白片高剂量组(750mg/kg.bw)和中剂量组(500mg/kg.bw)抗体积数显著高于空白对照组(P<0.05);
(4)、在抗体生成细胞检测(Jerne改良玻片法)中,本实施例的乳铁蛋白片高剂量组(750mg/kg.bw)、中剂量组(500mg/kg.bw)和低剂量组(250mg/kg.bw)空斑数显著高于空白对照组(P<0.05);
(5)、在NK细胞活性测定(乳酸脱氢酶测定法)中,本实施例的乳铁蛋白片高剂量组(750mg/kg.bw)、中剂量组(500mg/kg.bw)和低剂量组(250mg/kg.bw)NK细胞活性率显著高于空白对照组(P<0.05)。
6、结论
本发明的乳铁蛋白片具有增强免疫力的功能。
申请人声明,所属技术领域的技术人员在上述实施例的基础上,将上述实施例某组分的具体含量点值,与发明内容部分的技术方案相组合,从而产生的新的数值范围,也是本发明的记载范围之一,本申请为使说明书简明,不再罗列这些数值范围。
Claims (5)
1.一种乳铁蛋白片保健食品,其特征在于,所述乳铁蛋白片由乳铁蛋白、牛初乳粉、乳酸亚铁以及赋形剂制备而成。
2.如权利要求1所述的一种乳铁蛋白片保健食品,其特征在于,所述乳铁蛋白片每1000克由下述重量的原料制备而成:
乳铁蛋白 100克
牛初乳粉 400克
乳酸亚铁 12.9克
低聚半乳糖 227.5克
余下为赋形剂。
3.如权利要求1所述的一种乳铁蛋白片保健食品,其特征在于,每1000克乳铁蛋白片,所述赋形剂为:
D-甘露糖醇 45克
柠檬酸 9.6克
阿斯巴甜 3克
硬脂酸镁 2克。
4.如权利要求1所述的一种乳铁蛋白片保健食品的生产方法,其特征在于,包括如下步骤:
(1)过筛
将乳铁蛋白、牛初乳粉、乳酸亚铁、低聚半乳糖、柠檬酸、阿斯巴甜、D-甘露糖醇、硬脂酸镁分别过80目筛,称量备用;
(2)混合
将柠檬酸、阿斯巴甜和乳酸亚铁混合均匀,得混合粉1,将混合粉1和D-甘露糖醇按混合均匀,得混合粉2;将混合粉2、乳铁蛋白、牛初乳粉、低聚半乳糖置混合机中,混合20min,得总混合粉;
(3)制粒、干燥、整粒
用纯化水做润湿剂,制软材,过18目筛制颗粒;湿颗粒用热风循环烘箱干燥;所得干颗粒用16目筛整粒;
(4)总混、压片
将上述备用的硬脂酸镁加入所得颗粒中,置混合机混合5min,得总混颗粒;将上述所得总混颗粒压片,调节片重为0.8g/片;
(5)包装
用口服固体药用高密度聚乙烯瓶将上述所得合格片子进行包装;
(6)成品检验、入库
按照本产品企业标准规定抽取每批产品进行检验,将合格的产品进行入库。
5.如权利要求4所述的一种乳铁蛋白片保健食品的生产方法,其特征在于,步骤(3)所述的制粒、干燥、整粒中:
润湿剂的用量为总混合粉的30%;
干燥温度为50~55℃,干燥时间为30~40min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810148882.4A CN110115387A (zh) | 2018-02-05 | 2018-02-05 | 一种乳铁蛋白片保健食品及其生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810148882.4A CN110115387A (zh) | 2018-02-05 | 2018-02-05 | 一种乳铁蛋白片保健食品及其生产方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110115387A true CN110115387A (zh) | 2019-08-13 |
Family
ID=67519699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810148882.4A Pending CN110115387A (zh) | 2018-02-05 | 2018-02-05 | 一种乳铁蛋白片保健食品及其生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110115387A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117159702A (zh) * | 2023-09-19 | 2023-12-05 | 广州见华医学科技有限公司 | 一种乳铁蛋白胶囊在调节人体免疫力的用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102551073A (zh) * | 2012-02-22 | 2012-07-11 | 浙江康恩贝健康产品有限公司 | 一种含α-乳白蛋白和乳铁蛋白的营养组合物及其应用 |
CN103976359A (zh) * | 2014-05-23 | 2014-08-13 | 汤臣倍健股份有限公司 | 食品营养强化组合物及其应用、保健食品及其制备方法 |
CN104381782A (zh) * | 2013-08-19 | 2015-03-04 | 宣城柏维力生物工程有限公司 | 一种牛初乳柠檬酸钙咀嚼片及其制备方法 |
CN105998070A (zh) * | 2016-06-29 | 2016-10-12 | 广州联存医药科技股份有限公司 | 一种以牛初乳粉和乳矿物盐为原料的增强免疫力的制剂及其制备方法 |
-
2018
- 2018-02-05 CN CN201810148882.4A patent/CN110115387A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102551073A (zh) * | 2012-02-22 | 2012-07-11 | 浙江康恩贝健康产品有限公司 | 一种含α-乳白蛋白和乳铁蛋白的营养组合物及其应用 |
CN104381782A (zh) * | 2013-08-19 | 2015-03-04 | 宣城柏维力生物工程有限公司 | 一种牛初乳柠檬酸钙咀嚼片及其制备方法 |
CN103976359A (zh) * | 2014-05-23 | 2014-08-13 | 汤臣倍健股份有限公司 | 食品营养强化组合物及其应用、保健食品及其制备方法 |
CN105998070A (zh) * | 2016-06-29 | 2016-10-12 | 广州联存医药科技股份有限公司 | 一种以牛初乳粉和乳矿物盐为原料的增强免疫力的制剂及其制备方法 |
Non-Patent Citations (1)
Title |
---|
胡居吾等: "乳铁蛋白牛初乳颗粒增强免疫调节作用的研究", 《江西农业大学学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117159702A (zh) * | 2023-09-19 | 2023-12-05 | 广州见华医学科技有限公司 | 一种乳铁蛋白胶囊在调节人体免疫力的用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pearson et al. | Exploring the relationship between weaning and infant mortality: an isotope case study from Aşıklı Höyük and Çayönü Tepesi | |
CN101850002B (zh) | 一种具有改善营养性贫血功能的组合物 | |
WO2006071085A1 (en) | Tablet milk composition having immuno-modulating activity and preparation method thereof | |
CN104620853B (zh) | 一种富硒灵芝孢子粉或子实体的培育方法 | |
Anwar et al. | Changes in some hematological and serum biochemical parameters during the first week after lambing in six consecutive parities in some Egyptian sheep breeds | |
Adesanmi et al. | Nutritional quality of formulated complementary diet from defatted almond seed, yellow maize and quality protein maize flours | |
CN106722934A (zh) | 一种含地龙、沙蚕含肽提取物的抗衰保健食品 | |
CN110115387A (zh) | 一种乳铁蛋白片保健食品及其生产方法 | |
Turzhigitova et al. | A new environmentally safe phytopreparation increasing the protective function of calves | |
US20100316753A1 (en) | Formulations and methods for reducing abdominal fat and waist circumference | |
JPH0840B2 (ja) | 活性酸素抑制組成物及びその製造方法並びに血圧抑制剤 | |
LOPEZ et al. | Folic acid in the rehabilitation of persons with Sprue | |
CN110115294A (zh) | 一种乳铁蛋白颗粒保健食品及其生产方法 | |
Lentner et al. | The metabolic balance technique: a critical reappraisal | |
CN110115290A (zh) | 一种乳铁蛋白粉保健食品及其生产方法 | |
Miao et al. | Comparative study of camel milk from different areas of Xinjiang province in China | |
CN101085343B (zh) | 一种sod保健组合物 | |
CN109922816A (zh) | 包含花粉和/或雌蕊提取物的组合物、其制备工艺和相关用途 | |
CN104939098B (zh) | 一种增强骨免疫力、补钙锁钙的保健食品及其制备方法 | |
CN107050143A (zh) | 一种具有改善睡眠功效的配方、组合物及其制备方法 | |
Nkeudem et al. | Nutritional evaluation of commonly used local weaning food processed and sold in the Mount Cameroon Region | |
Heggarty et al. | Amino acid profile in Down's syndrome. | |
CN102335347A (zh) | 一种三七洋参软胶囊 | |
CN109998055A (zh) | 一种汉麻籽抗氧化多肽咀嚼片及其制备方法 | |
CN105685493A (zh) | 一种预防猪无名高热的饲料添加剂及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190813 |